CrystalGEM, a predictive and highly focussed crystallization screening invented by Chiralabs Ltd and marketed by Prosonix, is revolutionising the way that pharmaceutical companies undertake their crystallization screening activities, which are a critical and costly part of the drug development process.

CrystalGEM can be applied in discovery, process research, development, formulation, to molecules coming off patent and to troublesome crystallization systems to furnish you with: predictive solubility data in up to 902 solvent combinations, polymorph / habit proclivity, ideal processing solvents, samples of polymorphs, solvates and single crystals for X-ray diffraction studies, and all for using less than 200 mg of your valuable pharmaceutical ingredient. CrystalGEM can be applied to pharmaceutical crystallization R&D from selection of a drug candidate through to drug development and formulation.

Unlike other computational models which have historically attempted to predict crystallization from the molecular level and have shown to be of limited value, the structurally driven CrystalGEM technology developed by Chiralabs Ltd is based on the undertaking and analysis of thousands of real crystallization systems using single or mixed combinations of over 90 commercially available solvents, coupled to proven and proprietary pattern recognition algorithms. The CrystalGEM technology allows the prediction of solubility and an indication of the crystallization outcomes in mixed solvent conditions, including morphological and polymorphic proclivity.

Information on likely crystallization, morphology, habit and polymorphism are obtained allowing the efficient selection and ranking of conditions worth experimental exploration. Importantly the approach rapidly highlights the areas of solvent space that have the highest chance of delivering viable crystalline material, and hence suitable for scale up and manufacture. When coupled to in-house microcrystallization technology, compounds can be effectively and efficiently screened, often generating high quality single crystals suitable for further crystallographic analysis and absolute polymorph confirmation.

Amazingly, unlike other typical high throughout screening approaches, a full CrystalGEM study including the microcrystallization screen only requires around 200mg of compound, offering hitherto unattainable physical form data for discovery and lead optimisation. Classical random HTS approaches may now be obsolete.

Features:

• Structurally and outcome driven

• Uses proprietary pattern recognition technology and QSAR analysis of over 300 parameters

• Predicts probability and feasibility of morphology and polymorphism in silico

• Predicts optimum solvent conditions for desired outcome

• Draws on an in-house database of over 12,000 real experimental conditions

• Microcrystallization technique confirms prediction with only mg quantities of compound

• CrystalGEM Benefits to the Pharmaceutical Industry:

• Can be applied at any stage during pharmaceutical development

• Significantly reduces the time frame and cost for crystallization screening

• Results can be directly used by the industrial user

• Makes High Throughput Crystallization Screening obsolete

Become part of the next pharmaceutical crystallization revolution today!

Attachments:

File	File size
CrystalGEM.pdf	352 Kb